

Research evaluation



Pathophysiology, Targets and Therapies of Rheumatoid Arthritis (Li2P)

UNDER THE SUPERVISION OF THE FOLLOWING INSTITUTIONS AND RESEARCH BODIES:

Université Paris 13 Institut national de la santé et de la recherche médicale - Inserm

EVALUATION CAMPAIGN 2017-2018GROUP D



In the name of Hcéres¹:

Michel Cosnard, President

In the name of the expert committee²:

Jean Michel Dayer, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

¹ The president of Hcéres "countersigns the evaluation reports set up by the expert committees and signed by their chairman." (Article 8, paragraph 5);

² The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2).



This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

UNIT PRESENTATION

Unit name: Pathophysiology, Targets and Therapies of Rheumatoid Arthritis

Unit acronym: Li2P

Requested label: UMR U

Application type: Renewal

Current number: UMR U1125

Head of the unit

(2017-2018):

Mr Marie-Christophe Boissier

Project leader

(2019-2023):

Mr Marie-Christophe Boissier

Number of team:

COMMITTEE MEMBERS

Chair: Mr Jean Michel Dayer, University of Geneva, Switzerland

Experts: Ms Florence Apparallly, Inserm Montpellier (representative of Inserm CSS)

Mr Maxime Breban, APHP Boulogne-Billancourt (representative of CNU)

Ms Sophie Duchez, Université Paris Diderot (supporting personnel)

Mr Diego Kyburz, University of Basel, Switzerland

Mr Rik LORIES, KU Leuven, Belguim

HCERES scientific officer:

Ms Anne Caignard

Representatives of supervising institutions and bodies:

Ms Camille Chaudonneret, Inserm

Mr Didier Frandji Groupe, CHU

Ms Chantal Lasserre, Inserm

Ms Anne Pelle, Université Paris 13



INTRODUCTION

HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

Rheumatology research was introduced at the Paris 13 University (UP13) in Bobigny in 1991 within a UPRES (University research unit). From 1997 to 2004, the "Groupe de Recherche in immunopathologie et immuno-intervention" (Immunopathology and Immunointervention Research Group, UPRES 2361 then 3408), focused on "Rheumatoid arthritis" (RA) among its axes of investigation. The group obtained the Associated Training seal of approval from the Claude Bernard Association (1999-2004) and was subsequently granted an Inserm team status as "Contrat de Recherche Externe" (CRE), then as ER118 "Physiopathologie et Biothérapies de la Polyarthrite Rhumatoïde" (Pathophysiology and Biotherapies of Rheumatoid Arthritis, 2006-2008), and Inserm U1125 in 2014. This new status enabled further scientific development within UP13; the focus on this translational research aimed chiefly at rheumatoid arthritis (RA). The unit is located on the campus of Bobigny of the UP13, within the building of the UFR de Santé, médecine et biologie humaine (SMBH), Northeast of Paris.

MANAGEMENT TEAM

The research unit is headed by Mr Marie-Christophe Boissier.

HCERES NOMENCLATURE

SVE5: Physiologie, Physiopathologie, Cardiologie, Pharmacologie, Endocrinologie, Cancer, Technologies Médicales.

SCIENTIFIC DOMAIN

The team is focused on Rheumatoid Arthritis (RA), studying innate and adaptive immune cells and cytokine involvement. Its research is mostly pre-clinical, with an investment in appropriate murine models for testing new therapeutic principles.

UNIT WORKFORCE

Unit workforce	Number 30/06/2017	Number 01/01/2019	
Permanent staff			
Full professors and similar positions	5	7	
Assistant professors and similar positions	3	3	
Full time research directors (Directeurs de recherche) and similar positions	0	1	
Full time research associates (Chargés de recherche) and similar positions	0	0	
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	2	2	
High school teachers	0	0	



Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	5	4	
TOTAL permanent staff	15	17	
Non-permanent staff			
Non-permanent professors and associate professors, including emeritus	1		
Non-permanent full time scientists, including emeritus, post-docs	2		
Non-permanent supporting personnel	1		
PhD Students	5		
TOTAL non-permanent staff	9		
	-	_	
TOTAL unit	24		

GLOBAL ASSESSMENT OF THE UNIT

The unit has successfully translated the proof of concept studies in animal models to clinical trials with very high quality. In addition, other original approaches on new cytokines have been studied.

The scientific production is very good and the unit's reputation excellent. The unit has been highly active in communication of research by informing the public to general topics. The interaction with the non-academic world and the industry is excellent to outstanding. The involvement in training through research in a translational approach to clinic is one of the most important features of the unit and the quality is very high with excellent implication in Master programs. Only training in complementary skills such as learning to write manuscripts and grants is limited. The organization is excellent as well as the interaction with the clinical staff. However, teaching and clinical duties are important in the unit, and the time allocated to research by some clinical staff members appears somewhat limited. The management is transparent and consensual with an outstanding collaboration with the Institutions. University Paris 13 and hospital Institution are highly supportive. The research, teaching and clinical rheumatology has been a major implementation at the UP13 and Hospital.

The evaluation reports of Hceres are available online: www.hceres.com

Evaluation of clusters of higher education and research institutions Evaluation of higher education and research institutions **Evaluation of research Evaluation of doctoral schools Evaluation of programmes** International evaluation and accreditation



2 rue Albert Einstein 75013 Paris, France T. 33 (0)1 55 55 60 10

